Active Cancer Public Health & Healthcare

Risk factors, tumour biology and genetics of breast cancer in Cameroon: a pilot study

In plain English

AI plain-English summary

In Cameroon, a researcher will collect saliva and tumour samples from women with breast cancer to find out which genetic faults drive the disease in younger patients. Breast cancer is the most common cancer among women in sub-Saharan Africa, and a large proportion of cases occur before age 45. Yet no one knows how many of these early breast cancers are caused by inherited mutations in genes such as BRCA1 and BRCA2, which dramatically raise lifetime risk. The link between tumour hormone receptor status and inherited genetic variants has also never been studied in Cameroon. If this pilot work succeeds, it will reveal the proportion of early-onset breast cancers in Cameroon that are hereditary. That knowledge could eventually guide genetic testing and screening programmes tailored to the region, helping doctors identify women at high risk before cancer develops. It would also lay the groundwork for larger studies across sub-Saharan Africa, where the drivers of breast cancer in young women remain largely unknown.

View original technical description
Breast cancer is the most common cancer among women in sub-Saharan Africa (SSA) and more than 40% of women with breast cancer are diagnosed before age 45 in these settings. However, despite the high burden of breast cancer among younger women, the drivers of breast cancer pathogenicity and the proportion of early breast cancers attributable to hereditary causes is unknown. Pathogenic variants (PV) in BRCA1/2 genes are associated with a 60-80% increased lifetime risk of breast cancer. Furthermore, there are few studies that have investigated the association between the tumour hormone receptor status, and the presence of a PV in breast cancer susceptibility genes in SSA, and no such studies have been done in Cameroon. So, I will do a pilot study recruiting 150 women with a breast cancer diagnosed at age 45 or below and 150 women diagnosed after age 45 in Cameroon. For all patients, I will study their tumour hormone receptor status; for patients diagnosed at ? 45 years, or with a triple-negative breast cancer irrespective of age, a saliva sample will be collected for DNA extraction, to determine what proportion of these patients carry a germline pathogenic variant using whole exome sequencing.

View the original record at the funder ↗

Researchers

Yvonne Ateh Joko Walburga Epse Fru (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Identifying young women with high breast cancer risk-cervical sub-study
Identifying young women with high breast cancer risk-clinical study
Identifying young women with high breast cancer risk - Health Psychology
A prospective cohort study in women at increased life-time risk of developing breast cancer to look for blood-markers that would enable an earlier diagnosis of the disease.
`Analysis of neo-antigens and immune profiles of Asian breast cancer patients, focusing on common germline deletion of APOBEC3B cytosine deaminase

Original classification

Wellcome Accelerator Awards

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.